Having received two rituximab (Rituxan) infusions 15 days apart with resultant B‑cell depletion, may I start omalizumab (Xolair)?

Can You Start Omalizumab After Rituximab-Induced B‑Cell Depletion?

Yes, you can safely start omalizumab after rituximab-induced B‑cell depletion, as these two biologics target completely different immune pathways and do not have pharmacologic interactions that would preclude their use together.

Mechanistic Rationale

Rituximab and omalizumab operate through entirely distinct mechanisms that do not interfere with one another:

• Rituximab is a monoclonal antibody targeting CD20 on B lymphocytes, causing B‑cell depletion through complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity 1.

• Omalizumab is a monoclonal antibody that binds free IgE in serum, preventing IgE from binding to high-affinity receptors on mast cells and basophils, thereby blocking the allergic cascade 2.

Because omalizumab does not depend on B cells for its therapeutic effect—it targets circulating IgE molecules already produced—the absence of B cells after rituximab does not diminish omalizumab's efficacy 2.

Timing Considerations After Rituximab

Expected Duration of B‑Cell Depletion

After two 1‑g rituximab infusions given 15 days apart, B‑cell depletion typically persists for 6–12 months, though individual variation is substantial 1:

• In rheumatoid arthritis patients, the majority demonstrate near-complete CD19+ B‑cell depletion (< 20 cells/µL) within 2 weeks, with most patients showing peripheral B‑cell depletion for at least 6 months 1.
• B‑cell recovery generally begins around 6 months, with median B‑cell levels returning to normal by 12 months 1.
• A small proportion (~4%) experience prolonged B‑cell depletion lasting more than 3 years after a single course 1.
• In some patients, B‑cell depletion can extend as far as 22–23 months after a single infusion 3.

No Mandatory Waiting Period for Omalizumab

There is no evidence-based requirement to wait for B‑cell reconstitution before starting omalizumab 2. The decision to initiate omalizumab should be driven by:

1. Clinical indication (e.g., moderate-to-severe allergic asthma, chronic spontaneous urticaria) 2.
2. Stability of the underlying condition for which rituximab was given 2.
3. Absence of active infection or severe immunosuppression-related complications 2.

Safety Considerations

Infection Risk

The primary concern when combining or sequencing biologics after rituximab is cumulative immunosuppression and infection risk:

• Rituximab causes sustained reductions in IgM and IgG serum levels, with 14% of patients having immunoglobulin levels below normal range 5–11 months post-treatment 1.
• In repeated rituximab courses for rheumatoid arthritis, 23.3% of patients experienced IgM below the lower limit of normal, 5.5% had low IgG, and 0.5% had low IgA 1.
• Omalizumab does not cause B‑cell depletion or further suppress immunoglobulin production; it only binds free IgE 2.

Practical steps to mitigate infection risk:

• Measure serum immunoglobulin levels (IgG, IgM, IgA) before starting omalizumab 1.
• If IgG is significantly reduced (< 400 mg/dL), consider delaying omalizumab or providing immunoglobulin replacement therapy 4.
• Screen for latent infections (hepatitis B, tuberculosis) if not already done before rituximab 2.
• Ensure vaccinations (especially pneumococcal and influenza) were administered before rituximab or plan them for at least 6 months after rituximab and 4 weeks before the next cycle, recognizing that vaccine responses will be suboptimal during B‑cell depletion 2.

Omalizumab-Specific Safety

Omalizumab carries a risk of anaphylaxis (approximately 0.2% incidence), which can occur after any dose but is most common within the first 2 hours of the first three injections 2:

• Observation requirements: 2 hours after the first three doses, then 30 minutes for subsequent doses 2.
• Epinephrine autoinjector: All patients must be trained in recognizing anaphylaxis and have an epinephrine autoinjector immediately available 2.
• Omalizumab should only be administered in a facility equipped to treat anaphylaxis 2.

The presence of B‑cell depletion does not increase the risk of omalizumab-related anaphylaxis, as this reaction is IgE-mediated or involves direct mast cell activation, not B‑cell-dependent 2.

Clinical Algorithm for Starting Omalizumab After Rituximab

1. Confirm clinical indication for omalizumab (e.g., uncontrolled allergic asthma despite inhaled corticosteroids and long-acting beta-agonists, chronic spontaneous urticaria refractory to antihistamines) 2.

2. Assess stability of the condition treated with rituximab:

   • If rituximab was given for autoimmune disease (e.g., rheumatoid arthritis, vasculitis), ensure disease is in remission or stable 2.
   • If rituximab was given for lymphoma or other malignancy, coordinate with oncology to ensure no contraindication 1.

3. Check laboratory parameters:

   • Measure CD19+ B‑cell count (optional but helpful to document depletion status) 1.
   • Measure serum IgG, IgM, IgA levels 1.
   • If IgG < 400 mg/dL or recurrent infections are present, consider immunoglobulin replacement before starting omalizumab 4.

4. Screen for active infection:

   • Obtain complete blood count with differential 1.
   • Assess for signs/symptoms of infection (fever, cough, dysuria, etc.) 2.
   • If active infection is present, treat and resolve before starting omalizumab 2.

5. Administer omalizumab with appropriate monitoring:

   • First three doses: observe for 2 hours post-injection 2.
   • Subsequent doses: observe for 30 minutes 2.
   • Ensure epinephrine autoinjector is available and patient is trained in its use 2.

6. Monitor for complications:

   • Watch for signs of infection (fever, new respiratory symptoms, urinary symptoms) 2, 4.
   • Monitor immunoglobulin levels every 6 months if they were low at baseline 1.
   • Continue routine monitoring for the underlying condition treated with rituximab 2.

Common Pitfalls to Avoid

• Do not delay omalizumab unnecessarily waiting for B‑cell reconstitution, as omalizumab efficacy is independent of B‑cell status 2, 1.
• Do not assume omalizumab will worsen immunosuppression; it does not deplete B cells or suppress immunoglobulin production beyond binding free IgE 2.
• Do not skip the 2‑hour observation period for the first three omalizumab doses, even if the patient has received it before, as anaphylaxis can occur at any time 2.
• Do not overlook low immunoglobulin levels after rituximab; if IgG is significantly reduced, address this before adding another biologic 1, 4.
• Do not forget to ensure the patient has an epinephrine autoinjector and knows how to use it, as anaphylaxis can occur outside the observation window 2.